{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:36:31Z","timestamp":1793406991852,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00406-018-0959-2","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T01:48:22Z","timestamp":1543542502000},"page":"23-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993\u20132015"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-294X","authenticated-orcid":false,"given":"Michael","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Regente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"St\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"issue":"8","key":"959_CR1","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/0006-3223(87)90010-2","volume":"22","author":"G Addonizio","year":"1987","unstructured":"Addonizio G, Susman VL, Roth SD (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 22(8):1004\u20131020","journal-title":"Biol Psychiatry"},{"key":"959_CR2","volume-title":"Diagnostic and statistical manual of mental disorders DSM-IV-TR","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders DSM-IV-TR. Jaypee Medical Ltd, London"},{"key":"959_CR3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders DSM 5","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders DSM 5, 5 edn. American Psychiatric Association, London","edition":"5"},{"key":"959_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40268-014-0078-0","volume":"15","author":"M Belvederi Murri","year":"2015","unstructured":"Belvederi Murri M, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G et al (2015) Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs RD 15:45\u201362. https:\/\/doi.org\/10.1007\/s40268-014-0078-0","journal-title":"Drugs RD"},{"key":"959_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s001150050259","volume":"69","author":"T Bschor","year":"1998","unstructured":"Bschor T, Bauer M (1998) Thyroid gland function in lithium treatment. Nervenarzt 69:189\u2013195","journal-title":"Nervenarzt"},{"issue":"5","key":"959_CR6","first-page":"734","volume":"153","author":"B Buzan","year":"1996","unstructured":"Buzan B (1996) Risperidone-induced tardive dyskinesia. Am J Psychiatry 153(5):734\u2013735","journal-title":"Am J Psychiatry"},{"issue":"1","key":"959_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/01376517-199302000-00013","volume":"25","author":"C Byrd","year":"1993","unstructured":"Byrd C (1993) Neuroleptic malignat syndrome: a dangerous complication of neuroleptic therapy. J Neurosci Nurs 25(1):62\u201365","journal-title":"J Neurosci Nurs"},{"issue":"Suppl 4","key":"959_CR8","first-page":"12","volume":"63","author":"SN Caroff","year":"2002","unstructured":"Caroff SN, Mann SC, Campbell EC, Sullivan KA (2002) Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63(Suppl 4):12\u201319","journal-title":"J Clin Psychiatry"},{"key":"959_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2190\/PM.39.4.h","volume":"39","author":"Y Chen","year":"2009","unstructured":"Chen Y, Guo JJ, Steinbuch M, Buckley PF, Patel NC (2009) Risk of neuroleptic malignant syndrome in patients with bipolar disorder: a retrospective, population-based case-control study. Int J Psychiatry Med 39:439\u2013450","journal-title":"Int J Psychiatry Med"},{"key":"959_CR10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s001150050165","volume":"68","author":"AJ Fallgatter","year":"1997","unstructured":"Fallgatter AJ, Strik WK (1997) Reversible neuropsychiatric side effects of lithium with normal serum levels. A case report. Nervenarzt 68:586\u2013590","journal-title":"Nervenarzt"},{"issue":"4","key":"959_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyv126","volume":"19","author":"ME Friedrich","year":"2016","unstructured":"Friedrich ME, Akimova E, Huf W, Konstantinidis A, Papageorgiou K, Winkler D, Toto S, Greil W, Grohmann R, Kasper S (2016) Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program. Int J Neuropsychopharmacol 19(4):1\u20139. https:\/\/doi.org\/10.1093\/ijnp\/pyv126","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"959_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00406-013-0419-y","volume":"264","author":"R Grohmann","year":"2013","unstructured":"Grohmann R, Engel RR, M\u00f6ller H-J, R\u00fcther E, van der Velden JW, St\u00fcbner S (2013) Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study. Eur Arch Psychiatry Clin Neurosci 264(2):131\u2013141. https:\/\/doi.org\/10.1007\/s00406-013-0419-y","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"Suppl 1","key":"959_CR13","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1055\/s-2004-815505","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Engel RR, Ruther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):S4\u2013S11. https:\/\/doi.org\/10.1055\/s-2004-815505","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"959_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/acps.12694","volume":"135","author":"RJ Gurrera","year":"2017","unstructured":"Gurrera RJ (2017) A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. Acta Psychiatr Scand May 135(5):398\u2013408","journal-title":"Acta Psychiatr Scand May"},{"issue":"11","key":"959_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00228-007-0355-8","volume":"63","author":"D Kato","year":"2007","unstructured":"Kato D, Kawanishi C, Kishida I, Furuno T, Suzuki K, Onishi H, Hirayasu Y (2007) Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 63(11):991\u2013996","journal-title":"Eur J Clin Pharmacol"},{"key":"959_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1176\/ajp.148.7.880","volume":"148","author":"PE Keck","year":"1991","unstructured":"Keck PE, Pope HG, McElroy SL (1991) Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 148:880\u2013882. https:\/\/doi.org\/10.1176\/ajp.148.7.880","journal-title":"Am J Psychiatry"},{"key":"959_CR17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1176\/ajp.144.10.1344","volume":"144","author":"PE Keck","year":"1987","unstructured":"Keck PE, Pope HG, McElroy SL (1987) Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 144:1344\u20131346. https:\/\/doi.org\/10.1176\/ajp.144.10.1344","journal-title":"Am J Psychiatry"},{"key":"959_CR18","first-page":"352","volume":"50","author":"PE Keck","year":"1989","unstructured":"Keck PE, Sebastianelli J, Pope HG, McElroy SL (1989) Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. J Clin Psychiatry 50:352\u2013355","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"959_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/002580249303300118","volume":"33","author":"PA Lannas","year":"1993","unstructured":"Lannas PA, Pachar JV (1993) A fatal case of neuroleptic malignant syndrome. Med Sci Law 33(1):86\u201388","journal-title":"Med Sci Law"},{"issue":"3","key":"959_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/15622975.2017.1285048","volume":"19","author":"M Letmaier","year":"2018","unstructured":"Letmaier M, Grohmann R, Kren C, Toto S, Bleich S, Engel R, Gary T, Papageorgiou K, Konstantinidis A, Holl KA, Painold A, Kasper S (2018) Venous thromboembolism during treatment with antipsychotics\u2014results of a drug surveillance program. World J Biol Psychiatry 19(3):175\u2013186. https:\/\/doi.org\/10.1080\/15622975.2017.1285048","journal-title":"World J Biol Psychiatry"},{"key":"959_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1089\/cap.2014.0047","volume":"24","author":"G Masi","year":"2014","unstructured":"Masi G, Milone A, Viglione V, Mancini A, Pisano S (2014) Massive asymptomatic creatine kinase elevation in youth during antipsychotic drug treatment: case reports and critical review of the literature. J Child Adolesc Psychopharmacol 24:536\u2013542. https:\/\/doi.org\/10.1089\/cap.2014.0047","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"959_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1055\/s-2008-1076727","volume":"41","author":"EM Meisenzahl","year":"2008","unstructured":"Meisenzahl EM, Schmitt G, Gr\u00fcnder G, Dresel S, Frodl T, la Foug\u00e8re C et al (2008) Striatal D2\/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 41:169\u2013175. https:\/\/doi.org\/10.1055\/s-2008-1076727","journal-title":"Pharmacopsychiatry"},{"key":"959_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/jnnp.53.6.517","volume":"53","author":"AP Moore","year":"1990","unstructured":"Moore AP, Macfarlane IA, Blumhardt LD (1990) Neuroleptic malignant syndrome and hypothyroidism. J Neurol Neurosurg Psychiatry 53:517\u2013518","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"959_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1055\/s-0035-1553246","volume":"83","author":"M Nagel","year":"2015","unstructured":"Nagel M, Freisberg S, Junghanns K, Moll CKE, Willenborg B (2015) The neuroleptic malignant syndrome]. Fortschr Neurol Psychiatr 83:373\u2013380. https:\/\/doi.org\/10.1055\/s-0035-1553246","journal-title":"Fortschr Neurol Psychiatr"},{"key":"959_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/070674371205700810","volume":"57","author":"RE Nielsen","year":"2012","unstructured":"Nielsen RE, Wallenstein Jensen SO, Nielsen J (2012) Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry 57:512\u2013518. https:\/\/doi.org\/10.1177\/070674371205700810","journal-title":"Can J Psychiatry"},{"key":"959_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/NDT.S118438","volume":"13","author":"R Oruch","year":"2017","unstructured":"Oruch R, Pryme IF, Engelsen BA, Lund A (2017) Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatr Dis Treat 13:161\u2013175","journal-title":"Neuropsychiatr Dis Treat"},{"key":"959_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1592\/phco.28.4.530","volume":"28","author":"LS Picard","year":"2008","unstructured":"Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE (2008) Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 28:530\u2013535. https:\/\/doi.org\/10.1592\/phco.28.4.530","journal-title":"Pharmacotherapy"},{"key":"959_CR28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","volume":"280","author":"G Perrault","year":"1997","unstructured":"Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73\u201382","journal-title":"J Pharmacol Exp Ther"},{"key":"959_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1177\/1060028016657553","volume":"50","author":"DJ Pileggi","year":"2016","unstructured":"Pileggi DJ, Cook AM (2016) Neuroleptic malignant syndrome. Ann Pharmacother 50:973\u2013981. https:\/\/doi.org\/10.1177\/1060028016657553","journal-title":"Ann Pharmacother"},{"issue":"4","key":"959_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyu080","volume":"18","author":"CJ Spindelegger","year":"2014","unstructured":"Spindelegger CJ, Papageorgiou K, Grohmann R, Engel R, Greil W, Konstantinidis A et al (2014) Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010. Int J Neuropsychopharmacol 18(4):1. https:\/\/doi.org\/10.1093\/ijnp\/pyu080","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"959_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00004850-199609000-00009","volume":"11","author":"B Spivak","year":"1996","unstructured":"Spivak B, Gonen N, Mester R, Averbuch E, Adlersberg S, Weizman A (1996) Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. Int Clin Psychopharmacol 11(3):207\u2013209","journal-title":"Int Clin Psychopharmacol"},{"key":"959_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0924-9338(00)00402-8","volume":"15","author":"B Spivak","year":"2000","unstructured":"Spivak B, Maline DI, Kozyrev VN, Mester R, Neduva SA, Ravilov RS et al (2000) Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry 15:330\u2013333","journal-title":"Eur Psychiatry"},{"issue":"Suppl 1","key":"959_CR33","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1055\/s-2004-815511","volume":"37","author":"S St\u00fcbner","year":"2004","unstructured":"St\u00fcbner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neund\u00f6rfer G et al (2004) Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37(Suppl 1):S54\u2013S64. https:\/\/doi.org\/10.1055\/s-2004-815511","journal-title":"Pharmacopsychiatry"},{"key":"959_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/00005053-198804000-00007","volume":"176","author":"VL Susman","year":"1988","unstructured":"Susman VL, Addonizio G (1988) Recurrence of neuroleptic malignant syndrome. J Nerv Ment Dis 176:234\u2013241","journal-title":"J Nerv Ment Dis"},{"key":"959_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/acps.12222","volume":"130","author":"Y-P Su","year":"2014","unstructured":"Su Y-P, Chang C-K, Hayes RD, Harrison S, Lee W, Broadbent M et al (2014) Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand 130:52\u201360. https:\/\/doi.org\/10.1111\/acps.12222","journal-title":"Acta Psychiatr Scand"},{"key":"959_CR36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1570159X13999150424113345","volume":"13","author":"L Tse","year":"2015","unstructured":"Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F (2015) Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol 13:395\u2013406","journal-title":"Curr Neuropharmacol"},{"key":"959_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2190\/PM.49.1.c","volume":"49","author":"P-T Tseng","year":"2015","unstructured":"Tseng P-T, Chang Y-C, Chang C-H, Wang H-Y, Cheng Y-S, Wu C-K et al (2015) Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. Int J Psychiatry Med 49:35\u201343. https:\/\/doi.org\/10.2190\/PM.49.1.c","journal-title":"Int J Psychiatry Med"},{"issue":"6","key":"959_CR38","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/00004583-199211000-00028","volume":"31","author":"MM Woodbury","year":"1992","unstructured":"Woodbury MM, Woodbury MA (1992) Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 31(6):1161\u20131164","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"959_CR39","unstructured":"World Health Organisation (WHO) (2016) The international statistical classification of diseases and related health problems, ICD-10 2016 by World Health Organization (WHO) (2015-10-26)"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-018-0959-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-018-0959-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-018-0959-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:29:40Z","timestamp":1775287780000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-018-0959-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["959"],"URL":"https:\/\/doi.org\/10.1007\/s00406-018-0959-2","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]},"assertion":[{"value":"2 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T. Greiner, M. Schneider, S. Lensky, S. St\u00fcbner, J. Regente and M. Heinze declare no conflict of interests. The AMSP Drug Safety Program is based on non-profit associations in the German-speaking countries Germany, Austria and Switzerland. In recent years, financial support has been contributed by almost all the pharmaceutical companies involved in CNS research. Since 1993, educational and research grants have been awarded by the following pharmaceutical companies to the three national non-profit associations of the AMSP. Austrian companies: AstraZeneca \u00d6sterreich GmbH, Boehringer Ingelheim Austria, Bristol\u2013Myers Squibb GmbH, CSC Pharmaceuticals GmbH, Eli Lilly GmbH, Germania Pharma GmbH, GlaxoSmithKline Pharma GmbH, Janssen-Cilag Pharma GmbH, Lundbeck GmbH, Novartis Pharma GmbH, Pfizer Med Inform, Servier Pharma Austria, Wyeth Lederle Pharma GmbH. German companies: Abbott GmbH & Co. KG, AstraZeneca GmbH, Aventis Pharma Deutschland GmbH GE-O\/R\/N, Bayer Vital GmbH & Co. KG, Boehringer Mannheim GmbH, Bristol-Myers-Squibb, Ciba Geigy GmbH, Desitin Arzneimittel GmbH, Duphar Pharma GmbH & Co. KG, Eisai GmbH, esparma GmbH Arzneimittel, GlaxoSmithKline Pharma GmbH & Co. KG, Hoffmann-La Roche AG Medical Affairs, Janssen-Cilag GmbH, Janssen Research Foundation, Knoll Deutschland GmbH, Lilly Deutschland GmbH Niederlassung Bad Homburg, Lundbeck GmbH & Co. KG, Nordmark Arzneimittel GmbH, Novartis Pharma GmbH, Organon GmbH, Otsuka-Pharma Frankfurt, Pfizer GmbH, Pharmacia & Upjohn GmbH, Promonta Lundbeck Arzneimittel, Rhone-Poulenc Rohrer, Sanofi-Synthelabo GmbH, Sanofi-Aventis Deutschland, Schering AG, Servier Pharma, SmithKlineBeecham Pharma GmbH, Solvay Arzneimittel GmbH, Synthelabo Arzneimittel GmbH, Dr Wilmar Schwabe GmbH & Co., Thiemann Arzneimittel GmbH, Trommsdorff GmbH & Co. KG Arzneimittel, Troponwerke GmbH & Co. KG, Upjohn GmbH, Wander Pharma GmbH, Wyeth-Pharma GmbH. Swiss companies: AHP (Schweiz) AG, AstraZeneca AG, Bristol\u2013Myers Squibb AG, Desitin Pharma GmbH, Eli Lilly (Suisse) S.A., Essex Chemie AG, GlaxoSmithKline AG, Janssen-Cilag AG, Lundbeck (Suisse) AG, Mepha Schweiz AG\/Teva, MSD Merck Sharp & Dohme AG, Organon AG, Pfizer AG, Pharmacia, Sandoz Pharmaceuticals AG, Sanofi-Aventis (Suisse) S.A., Sanofi-Synthe\u00b4labo SA, Servier SA, SmithKlineBeecham AG, Solvay Pharma AG, Vifor SA, Wyeth AHP (Suisse) AG, Wyeth Pharmaceuticals AG. S. Bleich, R. Grohmann and S. Toto are project managers of the AMSP program. S. Toto has been a member of the advisory board for Otsouka and has received speaker\u2019s honoria from Janssen-Cilag, Lundbeck, Otsouka and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}